Remove Antibody Remove Bioavailability Remove RNA
article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?

Trials 83
article thumbnail

The Power of Lipids: Enhancing Drug Delivery with Nanoparticles

Roots Analysis

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.